Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen.

PubWeight™: 0.86‹?›

🔗 View Article (PMC 3499220)

Published in Cell Biosci on October 24, 2012

Authors

Bianca P Gomez1, Connie Wang, Raphael P Viscidi, Shiwen Peng, Liangmei He, T-C Wu, Chien-Fu Hung

Author Affiliations

1: Departments of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA. chung2@jhmi.edu.

Articles cited by this

Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science (2008) 16.60

Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol (2011) 6.13

Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell (2005) 5.90

T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci U S A (2008) 4.74

Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol (2008) 4.69

Merkel cell carcinoma: changing incidence trends. J Surg Oncol (2005) 3.78

MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol (2008) 3.29

Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res (2000) 2.91

Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer (2009) 2.77

Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol (2009) 2.63

Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest (2001) 2.61

Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol (2011) 2.52

Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res (2012) 2.48

A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J (2012) 2.45

The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J Immunol (1992) 2.27

Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res (2001) 1.75

Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol (2004) 1.66

An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int J Cancer (2011) 1.49

The etiology and epidemiology of merkel cell carcinoma. Curr Probl Cancer (2010) 1.39

Merkel cell polyomavirus-specific CD8⁺ and CD4⁺ T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res (2011) 1.36

Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study. Clin Cancer Res (2012) 1.29

Merkel cell polyomavirus in cutaneous swabs. Emerg Infect Dis (2010) 1.25

Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine (2007) 1.12

Complete spontaneous regression of metastatic merkel cell carcinoma: a case report and review of the literature. Am J Dermatopathol (2010) 1.11

Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res (2003) 1.10

Spontaneous regression of recurrent and metastatic Merkel cell carcinoma. J Dermatol (2007) 0.99

Development of a DNA vaccine targeting Merkel cell polyomavirus. Vaccine (2011) 0.95

Comparable expression and phosphorylation of the retinoblastoma protein in Merkel cell polyoma virus-positive and negative Merkel cell carcinoma. Int J Cancer (2010) 0.94

Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine (2004) 0.85

The standard of care for Merkel cell carcinoma should include adjuvant radiation and lymph node surgery. J Am Acad Dermatol (2002) 0.80

Articles by these authors

Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med (2009) 5.25

Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A (2005) 3.18

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81

Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem (2007) 2.62

Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci (2007) 2.31

How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23

Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res (2005) 2.21

Serologic evidence for exposure to simian virus 40 in North American zoo workers. J Infect Dis (2004) 1.98

A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res (2009) 1.79

Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 1.72

Population genetics of microbial pathogens estimated from multilocus sequence typing (MLST) data. Infect Genet Evol (2005) 1.72

Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71

Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68

Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol (2004) 1.66

Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62

A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61

Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 1.56

Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol (2009) 1.55

Phylogenomics and molecular evolution of polyomaviruses. Adv Exp Med Biol (2006) 1.54

Prospects of RNA interference therapy for cancer. Gene Ther (2006) 1.52

Lack of serological evidence for an association between simian virus 40 and lymphoma. Int J Cancer (2003) 1.51

Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50

Inducible re-expression of HEXIM1 causes physiological cardiac hypertrophy in the adult mouse. Cardiovasc Res (2013) 1.45

Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res (2007) 1.43

Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther (2007) 1.40

Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res (2007) 1.39

Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine (2009) 1.38

DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther (2007) 1.37

Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study). Cancer Epidemiol Biomarkers Prev (2011) 1.37

Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest (2012) 1.37

A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis (2004) 1.36

Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada. Oral Oncol (2007) 1.34

Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res (2005) 1.32

Focus on endometrial and cervical cancer. Cancer Cell (2004) 1.32

Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res (2012) 1.31

Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.30

A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States. J Infect Dis (2012) 1.30

Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis (2009) 1.29

Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29

Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev (2007) 1.28

Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol (2004) 1.27

Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem (2003) 1.27

Population genetic estimation of the loss of genetic diversity during horizontal transmission of HIV-1. BMC Evol Biol (2006) 1.27

Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27

Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther (2005) 1.26

Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res (2006) 1.26

Vaccination to prevent and treat cervical cancer. Hum Pathol (2004) 1.25

Comparing phylogenetic codivergence between polyomaviruses and their hosts. J Virol (2006) 1.25

Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24

Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res (2004) 1.24

A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine (2006) 1.24

Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther (2006) 1.24

Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther (2007) 1.23

Management and outcome of bleeding pseudoaneurysm associated with chronic pancreatitis. BMC Gastroenterol (2006) 1.23

Activation of Akt as a mechanism for tumor immune evasion. Mol Ther (2008) 1.22

Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther (2008) 1.22

Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol (2003) 1.21

Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) (2011) 1.21

Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause (2014) 1.21

Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 1.21

Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother (2005) 1.19

Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18

Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther (2002) 1.17

Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther (2007) 1.17

B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol (2005) 1.16

Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res (2009) 1.14

Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res (2012) 1.13